by Fred Goldstein, Gregg Masters and Douglas Goldstein
Listen to the episode here:
In our second month end ‘news/e/um‘ style PopHealth Week Review this Wednesday June 24 at 9 AM PT/12 PM ET we’ll feature hot topics in the news. Our regular panel of Fred Goldstein @fsgoldstein, Gregg Masters @2healthguru and Doug Goldstein @efuturist will identify newsworthy stories and offer commentary along the way. The initial slate of stories in the news includes:
- Healthways revised guidance
- Fitbit’s IPO and Garmin’s lawsuit
- Ochsner Health System
- What they are getting, news about Apple Watch – Chronic Care Management
- News B4 the Release – what they are working on the “New Mission Control”
- The physician led ACO management company Aledade’s VC raise
- Insights from the Personalized Medicine Coalition Study
- Anthem’s sparring bids for CIGNA (and Aetna’s pursuit of Humana) Could the ‘Big Five’ be reduced to the ‘Big Three’?
Here’s some background:
Healthways: A Perenial Disappointment?
This company just reported revised downward guidance and their stock was hammered. Last month, on May 18th their longtime CEO Ben Leedle stepped down and last year a group of dissident sharedholders filed to take over the Board, though they ultimately came to an agreement with a few of them joining the Healthways Board. As one of the largest population health companies, with unique programs like Silver Sneakers, the Gallup-Healthways Well-Being Index, and relationships with Blue Zones and Dean Ornish, how can they miss? Well the irreverent 3 have some thoughts you don’t want to miss this.
We’re sourcing our discussion from recent news: ‘Healthways Revises Financial Guidance for 2015‘ and Healthways (HWAY) Stock Sinks on Lower Full Year Revenue Guidance
Fitbit: The Wallstreet Darling of the Wearables Industry?
Fitbit went public, Woohoo! Lets take a walk as we discuss:
- the opportunities for wearables
- Fitbit’s first day pop (can you say JUMP) you know, we can get them to exercise, but hey its only the first month, is it sustainable?; and
- the recently announced Garmin lawsuit (what? So they hired employees from a competitor….. but maybe… they took more than their minds with them)
The good here, and some questions, here and here. And then there’s the ‘always-in America’ litigation angle via ‘Fitbit Sued by Jawbone for ‘Plundering’ Employees, Secrets‘ with all the gory details of the complaint here.
Ochsner Health System: The New Normal?
Doug Goldstein recently visited Ochsner Health and has some interesting insights to bring us. Perhaps more interesting is this announcement:
We all know how much buzz the product (better yet, platform) has produced in the digital health and exploding apps market, we’ll lean into the real world implications for its deployment to population health via Ochsner’s first mover vision inside their EHR.
…it’s not about the wearable – it’s about the “new mission control” being built into the EPIC workflow that will change how doctors support patients in life, fitness, health and healthcare.’ Douglas Goldstein
Aledade: The Physician Led ACO Management Company “ACOcor” Revisited?
Aledade just completed a $30 million series B raise, see; ‘Bethesda health tech company raises $30 million‘. What implications if any can we draw from this continuing investor confidence in the approach and ‘secret sauce’ enabling the transformation of the U.S. healthcare ecosystem from volume to value? What does this say about the ACO market writ larger and the continued embedding of the ACA’s moving parts as the new normal for American healthcare? For discussion of this milestone event, see: Leading the Transformation: Aledade’s Growth authored by Aledade CEO Farzad Mostahari, MD.
Themes: ACOs continue their market penetration, and the need for physician led ACOs can only be expected to continue to grow as well. Someone need fill that void. Aledade intends to be a front runner.
ACA repeal types are increasingly irrelevant and the King V Burwell trial decision – which could hit this week – is likely to only affirm the continued availability of Federal subsidies language issues notwithstanding.
Physician led ACOs are another shot at the bow of traditional hospital system led innovations including any ACOs the sponsor.
Personalized Medicine Coalition Study
Most of us have heard about the 17 year time-line for innovation to transfer from ‘bench to bedside’ into mainstream medicine. Clearly in days past, we could tolerate such a delayed ‘on-ramp’. Yet in the Internet age, with M0ore’s Law and the explosion medical information and informatics, plus opportunities for crowd sourcing and the connected global village are within the means of anyone carrying a smartphone, laptop of PC, such a delay is unacceptable.
Yet, there’s more in the way of innovation uptake. A recent study by the Precision Medicine Coalition outlines some of these concerns, particularly as it relates to ‘alternate payment models’ (APMs):
‘..as APMs continue to develop and these, and other alternate models are proposed, it will be important to consider what effect changing incentives and payment systems will have on the decision by interested stakeholders to invest in personalized medicine. The Report concludes that “if new incentives begin to hamper access to personalized medicines in a meaningful way, the ability to invest in research and development of highly personalized therapies and diagnostics will likely shift to align with the inflexible payment systems.”
“Understanding the dynamics and challenges facing the industry as payors move toward APMs is the first step to ensuring that these therapies can continue to be developed and made available to patients. This Report is an important first step to raising the awareness of these issues as payment models continue to evolve.’
Practical Impact or ‘Reading the Tea Leaves’
As the challenge of integrating the promise of precision medicine (utility of biomarkers and better understanding of disease pathology and associated risk management opportunities) informing and guiding to day to day lifestyle (including health) choices, another potential uptake inhibitor are the hoops payors or risk bearing organizations may require before deeming the application of such technology to better patient outcomes. So in a way, it’s not just about tech innovation adding value to medicine and healthcare, but also the bureaucracies we create to protect the public while stimulating innovation.
PM remains an on the come potential to current medical practice. The theory is compelling, but the 17 year bench to bedside standard is not likely to step aside any time soon. Perhaps incentives [and compelling outcomes studies] can accelerate an otherwise glacial pace of [tech transfer] adoption.
Anthem’s Determined Dance to Acquire CIGNA
Are we revisiting the Big 6, then Big 4, and ultimately fill in the ____ of the too big to fail accounting firms [RIP Arthur Anderson’ but now squarely laid at the feet of America’s Health Insurance Industry market leaders….
Themes: Is health plan consolidation the antidote to counter the recent and persistent wave of hospital, health system and medical group mergers? One CEO’s post merger standing in way of merger. Will investors stand by and watch a premium bid sit idle?
Bottomline? Might market consolidation for price leverage (and oh yeah, scale and operating efficiencies) enable the construction of a virtual single payor (or Ellwood vision of “SuperMeds”) via acquisitions or arrangements? Is this scale required by ACA as some opine? Or just more opportunity to generate fees and exit packages for senior executives? When has scale reduced costs?
So pull up a chair, get out on a walk, put on your headset, and tune in to PopHealth Week!